Advances in the treatment of malignant gliomas.


Journal Article (Review)

Local control with surgery, radiation, and temozolomide chemotherapy remain the pillars of treatment for high-grade gliomas. Novel therapeutic strategies, including a variety of antiangiogenic agents, are under investigation. One of these agents, bevacizumab, was recently given accelerated approval by the US Food and Drug Administration as a single agent for recurrent glioblastoma. Recent trial results are generating important clinical questions regarding which patients to treat and when, and how best to monitor response. Encouraging results of recent studies are driving willingness to undertake aggressive treatment and to improve outcomes in this population. In this era, better understanding of biology, molecular aspects of cancer, and clinical trial methodology are crucial for clinicians. This review focuses on recent advances in the treatment malignant gliomas, especially antiangiogenic therapy.

Full Text

Duke Authors

Cited Authors

  • Khasraw, M; Lassman, AB

Published Date

  • January 2010

Published In

Volume / Issue

  • 12 / 1

Start / End Page

  • 26 - 33

PubMed ID

  • 20425605

Pubmed Central ID

  • 20425605

Electronic International Standard Serial Number (EISSN)

  • 1534-6269

Digital Object Identifier (DOI)

  • 10.1007/s11912-009-0077-4


  • eng

Conference Location

  • United States